Journal of Clinical Oncology, Vol 6, 44-50, Copyright © 1988 by American Society of Clinical Oncology

ARTICLES

Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma

O Hartmann, CR Pinkerton, T Philip, JM Zucker and F Breatnach
Pediatric Department, Institut Gustave-Roussy, Villejuif, France.

Between January and December 1985, 17 children with advanced neuroblastoma who were greater than 1 year old (16 stage IV, one stage III) were administered cisplatin (CPDD, 200 mg/m2) and etoposide (VP- 16, 500 mg/m2) as a pilot study of toxicity and response rates for the European Neuroblastoma Study Group (ENSG). The study was designed to assess toxicity of two courses of treatment, and evaluate response rates after this short therapy. The creatinine clearance declined in seven of 15 patients. No patient experienced clinically significant hearing loss, but formal audiometric assessment of nine children revealed characteristic high tone loss in seven patients. Peripheral neuropathy was not seen. Asymptomatic hypomagnesemia (less than 0.7 microEq/L) was frequent, despite routine supplementation. Asymptomatic electrolyte imbalances occurred frequently, but were generally transient. Myelosuppression was severe, but brief. Seven patients required platelet transfusions and seven were readmitted between courses due to febrile episodes while neutropenic. There were no treatment-related deaths. According to strictly defined criteria, 12 of 17 patients showed a partial response (PR), and extensive marrow evaluation showed complete clearing of disease in six of 15 patients. This high-dose regimen, if carefully supervised, is associated with acceptable toxicity, comparable to that seen when the dose of CPDD is spread over several months. The rapidity and degree of response was encouraging and merits further evaluation.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. Cushing, R. Giller, J. W. Cullen, N. M. Marina, S. J. Lauer, T. A. Olson, P. C. Rogers, P. Colombani, F. Rescorla, D. F. Billmire, et al. Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882 J. Clin. Oncol., July 1, 2004; 22(13): 2691 - 2700. [Abstract] [Full Text] [PDF]

				B. W. Blakley, A. K. Gupta, S. F. Myers, and S. Schwan Risk Factors for Ototoxicity due to Cisplatin Arch Otolaryngol Head Neck Surg, May 1, 1994; 120(5): 541 - 546. [Abstract] [PDF]